180 Life Sciences
在场
180 Life Sciences 是一家在股票代码 ATNF (US) 下上市的公司。
高管
查看带有其 5 名主要高管的组织结构图
180 Life Sciences 搜索最多的简介
- Blair Jordan, Director and Interim Chief Executive Officer
- Stephen Shoemaker, Director
- Jay Goodman, Director
高管在180 Life Sciences变化
- Stephen Shoemaker已作为Director加入公司 (新闻发布的2024十二月5号).
- Omar Jimenez已作为Chief Financial Officer加入公司 (新闻发布的2024九月13号).
- Jim Woody, Chief Executive Officer and Director, 已经离开公司 (新闻发布的2024五月17号).
创建提醒
跟踪 180 Life Sciences 的高管变动
生物技术
180 Life Sciences 拥有 2,337 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Aadi Bioscience 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
- OraSure Technologies has announced the acquisition of Sherlock Biosciences (公布2024十二月20号).
- SiteOne Therapeutics 刚刚宣布为 100 筹款数百万美元。 (公布2024十二月20号).
生物技术 行业的其他推荐联系人
消息
180 Life Sciences 的最新新闻稿
- 180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors
- Press Releases
- 180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
- 180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
- 180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
- 180 Life Sciences Corp. - Corporate Updates
- 180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
- 180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
- 180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
- 180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
- View more press releases Close
通过电子邮件
